Skip to main content

Table 1 Sample characteristics for cross sectional survey (n = 380)

From: Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS)

Setting of questionnaire completion  
Hospital outpatient 266 (70%)
Hospital inpatient 18 (4.7%)
Participant’s home 93 (24.5%)
Other/not known 3 (0.8%)
Gender  
Male 231 (60.8%)
Female 149 (39.2%)
Age  
Median (range) 69 (38–91)
<65 113 (29.7%)
≥65 267 (70.3%)
Marital status  
Single 33 (8.7%)
Married / partnered 275 (72.4%)
Divorcer / separated 26 (6.8%)
Widowed 45 (11.8%)
Not known 1 (0.3%)
Ethnicity  
White British 326 (85.8%)
White Other 27 (7.1%)
Black 12 (3.2%)
Asian 10 (2.6%)
Other 5 (1.3%)
Religion  
Atheist 34 (8.9%)
Christian 305 (80.3%)
Muslim 7 (1.8%)
Other 21 (5.5%)
Not known 13 (3.4%)
Highest educational level  
Did not finish school 27 (7.1%)
Secondary school graduate 183 (48.2%)
College / technical qualification 88 (23.2%)
University first degree 37 (9.7%)
University higher degree 21 (5.5%)
Not known 24 (6.3%)
Occupation status  
Working or student 49 (12.9%)
Not working 47 (12.4%)
Retired 283 (74.5%)
Not known 1 (0.3%)
ECOG performance status  
0 133 (35.0%)
1 146 (38.4%)
2 64 (16.8%)
3 36 (9.5%)
4 1 (0.3%)
Treatment status  
Off treatment 199 (52.4%)
On treatment 181 (47.6%)
- High dose treatment with stem cell support 5 (1.3%)
- Chemotherapy / targeted therapy alone 141 (37.1%)
- Maintenance treatment 35 (9.2%)
Disease phase  
Newly diagnosed 79 (20.8%)
Stable / plateau phase 174 (45.8%)
Relapsed / progressive 127 (33.4%)
Immunoglobulin type  
IgG 227 (59.7%)
IgA 79 (20.8%)
IgM 3 (0.8%)
Light chain 65 (17.1%)
Non-secretory 4 (1.1%)
Not known 2 (0.5%)
ISS Stage at diagnosis  
I 105 (27.6%)
II 83 (21.8%)
III 81 (21.3%)
Not known 111 (29.2%)
Months since diagnosis  
0-12 101 (26.6%)
13-24 63 (16.6%)
25-36 31 (8.2%)
37-48 36 (9.5%)
Over 48 127 (33.4%)
Not known 22 (5.8%)